Scholarlink

<p>Efficient pathogen recognition must be tightly regulated to prevent immunopathology. Here, we identify PTIR1, a primate-specific splice variant of <i>DDX</i>58 lacking exon 4 and encoding a truncated RIG-I isoform, as a negative regulator of innate immune signaling. PTIR1 is selectively induced upon viral infection or interferon (IFN) stimulation, and its ectopic expression via adenoviral delivery broadly suppresses inflammatory responses in vivo. Mechanistically, PTIR1 activates the deubiquitinase UCHL5 to limit STAT1 ubiquitination at lysine 525, thereby impairing STAT1 nuclear translocation and dampening type I and type II IFN responses. Accordingly, in a model of autoimmune hepatitis, PTIR1 restricts IFN-γ-driven inflammation, and in a viral infection model, it attenuates type I IFN responses. PTIR1 also modulates RIG-I signaling by interfering with its dimerization, reducing its ubiquitination, and disrupting its interaction with MAVS, thereby limiting RIG-I-mediated antiviral recognition and facilitating viral immune evasion. These findings identify PTIR1 as an inducible post-transcriptional checkpoint that fine-tunes antiviral and inflammatory signaling to preserve tissue integrity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual effects of the alternative spliced RIG-I isoform PTIR1 on host antiviral defense and immune homeostasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月10日

查看全文
  • Jia Song,
  • Wenyu Tian,
  • Lulu Liu,
  • Xuyang Zhao,
  • Wei Zhao,
  • Dan Lu

摘要

Efficient pathogen recognition must be tightly regulated to prevent immunopathology. Here, we identify PTIR1, a primate-specific splice variant of DDX58 lacking exon 4 and encoding a truncated RIG-I isoform, as a negative regulator of innate immune signaling. PTIR1 is selectively induced upon viral infection or interferon (IFN) stimulation, and its ectopic expression via adenoviral delivery broadly suppresses inflammatory responses in vivo. Mechanistically, PTIR1 activates the deubiquitinase UCHL5 to limit STAT1 ubiquitination at lysine 525, thereby impairing STAT1 nuclear translocation and dampening type I and type II IFN responses. Accordingly, in a model of autoimmune hepatitis, PTIR1 restricts IFN-γ-driven inflammation, and in a viral infection model, it attenuates type I IFN responses. PTIR1 also modulates RIG-I signaling by interfering with its dimerization, reducing its ubiquitination, and disrupting its interaction with MAVS, thereby limiting RIG-I-mediated antiviral recognition and facilitating viral immune evasion. These findings identify PTIR1 as an inducible post-transcriptional checkpoint that fine-tunes antiviral and inflammatory signaling to preserve tissue integrity.